SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

OPEN is trending due to a recent share offering and the announcement of tradable warrants, leading to mixed reactions from investors. The community is debating the implications of potential dilution versus the benefits of rewarding shareholders, as well as the new CEO's vision for the company. Sentiment is further influenced by broader market conditions and the stock's volatile price action.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI (SOUN) is trending amid discussions around its latest earnings report, where revenue exceeded expectations and full-year guidance was raised. Community members are focused on the company's growth prospects, particularly its expansion into new markets and partnerships. While some express concerns about profitability, others highlight the company's strong cash position and potential for long-term growth in the AI sector.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending as community members discuss its recent price surge and potential for further gains, with some comparing it to Bitcoin and highlighting its privacy features. The conversation also includes speculation about market manipulation and potential pullbacks, alongside comparisons to other cryptocurrencies like DASH. Discussions also point to reduced liquid supply potentially amplifying volatility.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as the community digests mixed signals including earnings results, guidance, and a new ESPN partnership. While some investors express concern over revenue estimates, others highlight a significant share buyback program and potential benefits from the ESPN integration and expansion into prediction markets. Community sentiment appears divided as they await further details from the earnings call.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is trending as investors digest recent earnings results and debate whether the stock is undervalued, with some seeing the dip as a buying opportunity. Community discussion revolves around revenue growth, guidance, and the potential impact of competition, including Amazon, on the ad tech company's market share. Analysts are weighing in with updated ratings and price targets, contributing to the heightened interest in TTD.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

KODK is trending amid community excitement around its potential in pharmaceuticals and batteries, with some drawing parallels to meme stock surges. Discussions revolve around the company's near-term catalysts, pension benefits, and strategic partnerships, while others eagerly anticipate updates from the company's management on new and existing ventures. Some believe upcoming news could spark a significant rally, highlighting the stock's potential to disrupt key industries and deliver long-term value.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending downwards as investors express concerns about the company's acquisition of Hawthorne Airport despite a successful fundraising round, causing discussion about cash burn and future prospects. The community is actively debating the strategic rationale of the airport purchase, potential partnerships (such as with Tesla), and upcoming catalysts like the Dubai Airshow. Some traders are seeing the dip as a buying opportunity, while others are wary of further dilution and await concrete progress on aircraft certification and commercialization.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

The crypto token $SLAP is trending, with community members actively promoting and expressing bullish sentiment. Discussions frequently mention related tokens like $BROKE, $RAGE, $WAGMI, and $CAW, suggesting a collaborative community effort. Recent partnerships and sponsorships, including with an MMA fighter, are also being highlighted as potential growth catalysts.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid discussions about the company's financial performance, revenue, and association with Truth Social. The community is focused on the stock's volatility, potential risks, and the broader implications of Trump's political actions. Some traders speculate on pump-and-dump schemes and the stock's long-term viability.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending downwards amidst concerns about AI infrastructure financing and export restrictions to China, despite reaffirmations of strong AI chip demand; the community is debating whether this is a buying opportunity or the start of a larger correction, with some citing Michael Burry's short position as a warning sign.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>QOL Medical will buy Evoke for $11 per share, representing a premium of about 140% from the stock’s closing price on Monday.&nbsp;</li><li>The transaction has been approved by the boards of both companies and is expected to close by the end of 2025.</li><li>QOL Medical intends to finance the transaction with cash on hand. &nbsp;</li></ul>Shares of Evoke Pharma, Inc. (EVOK) more than doubled on Tuesday after the company said that it has entered into a definitive agreement to be acquired by privately-held QOL Medical for $11 per share.The purchase price represents a premium of about 140% from the stock’s closing price on Monday.Following the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/04/3180135/28255/en/Evoke-Pharma-Enters-into-Definitive-Agreement-to-Be-Acquired-by-QOL-Medical.html">announcement</a>, <a href="https://stocktwits.com/symbol/EVOK">EVOK shares</a> shot up 134% by Tuesday afternoon to hit $10.72 as of the time of writing, but still remained below the deal price.<h2 class="st-heading-2">Terms Of The Deal</h2>Florida-based QOL Medical will initiate a tender offer to acquire all outstanding shares of Evoke through a subsidiary. Once the tender offer is completed, a unit of QOL Medical will merge with Evoke.&nbsp;The transaction has been approved by the boards of both companies and is expected to close by the end of 2025. QOL Medical intends to finance the transaction with cash on hand.Evoke noted that the deal reflects the strategic value of Gimoti, the company’s nasal spray for the treatment of symptoms of acute and recurrent diabetic gastroparesis in adults. Diabetic gastroparesis is a chronic condition where the stomach takes too long to empty due to nerve damage caused by poorly controlled diabetes. Symptoms include nausea, vomiting, and bloating, among others.The gastric delay caused by gastroparesis can compromise absorption of orally administered medications, and until approval of Gimoti, treatment was available only in oral and injectable formulations.“GIMOTI strengthens our GI portfolio and advances our mission to support patients living with rare and underserved gastrointestinal conditions,” QOL Medical CEO Derick Cooper said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around EVOK jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume fell from ‘high’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:621/59;" src="data:image/png;base64,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" width="621" height="59" alt="EVOK's Sentiment Meter and Message Volume as of 1:29 p.m. ET on Nov. 4, 2025 | Source: Stocktwits"><figcaption>EVOK's Sentiment Meter and Message Volume as of 1:29 p.m. ET on Nov. 4, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user applauded the stockholders.<stembedurl>https://stocktwits.com/erb71/message/634823600</stembedurl>EVOK stock is up by 143% this year and by 87% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/stellantis-recalls-over-320000-jeep-plug-in-hybrids-in-us-over-fire-risk/cL28S1PR36n">Stellantis NV Recalls Over 320,000 Jeep Plug-In Hybrids In US Over Fire Risk</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

EVOK Stock Doubled In Value Today Post QOL Medical Deal, But Still Fails To Hit $11 Mark

Evoke noted that the deal reflects the strategic value of Gimoti, the company’s nasal spray for the treatment of symptoms of acute and recurrent diabetic gastroparesis in adults.

Equity

Shareholder Alert: The Ademi Firm investigates whether Evoke Pharma Inc. is obtaining a Fair Price for its Public Shareholders

Shareholder Alert: The Ademi Firm investigates whether Evoke Pharma Inc. is obtaining a Fair Price for its Public Shareholders Shareholder Alert: The Ademi Firm investigates whether Evoke Pharma Inc...

EVOK Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Evoke Pharma, Inc. is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Evoke Pharma, Inc. (NASDAQ: EVOK) to QOL Medical, LLC for $11.00 per share in cash is fair to Evoke shareholders...

Evoke Pharma's stock soared 168% on Wednesday after the company announced it had received a new U.S. patent that could extend the market life of Gimoti, its nasal spray treatment for gastroparesis.The patent, once issued, would provide Evoke with added protection through December 2036, covering the use of the drug in patients with moderate to severe symptoms of the condition.&nbsp;Gastroparesis impairs the stomach’s ability to empty, often rendering oral medications less effective.&nbsp;Evoke plans to list the new patent in the FDA’s Orange Book, which would extend exclusivity for Gimoti beyond its current timeline.The news comes alongside improving financials. In the first quarter of 2025, Evoke generated approximately $3.1 million in product sales, nearly doubling its revenue from the same period a year earlier.&nbsp;The company reported a net loss of $1.3 million, which&nbsp;translates to a loss of $0.51 per share, representing an improvement from the $1.6 million loss, or $2.09 loss per share, in the same quarter last year.Spending also ticked up, driven mainly by higher fees and profit-sharing with Eversana, its commercial partner.&nbsp;Operating expenses totaled $4.4 million, up from $3.2 million a year earlier.As of March 31, Evoke had $12.6 million in cash.&nbsp;Based on its current plans, it expects to carry operations into the second quarter of 2026.&nbsp;The company is also sticking to its 2025 sales goal of $16 million, which would be a 60% increase from last year if current trends continue.On Stocktwits, retail sentiment for Evoke was ‘extremely bullish’ amid ‘extremely high’ message volume.One user mentioned buying 100 lots of Evoke’s stock and said they were waiting for a potential move to cover.&nbsp;<stembedurl>https://stocktwits.com/mikefromclt/message/620413256</stembedurl>Another user expressed a bullish outlook as well, saying they were fully loaded on the stock and planned to hold their position into the next session.<stembedurl>https://stocktwits.com/stocksweets/message/620411085</stembedurl><a href="https://stocktwits.com/symbol/EVOK">Evoke’s stock</a> has risen 56.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Evoke Pharma (EVOK) received a new U.S. patent that could extend the market life of Gimoti/ Photo credit: Getty Images

Evoke Pharma Stock Skyrockets On Patent For Nasal Spray That Eases Stomach Delays; Retail Bulls Pile In

The newly allowed patent covers the use of Gimoti in patients with moderate to severe gastroparesis and is expected to extend market exclusivity through 2036. 

Evoke shares drop 15% as loss widens despite revenue growth

Evoke expects earnings to exceed market expectations, shares jump

Monte Rosa Therapeutics Inc. (<a class="mention" data-mention="$GLUE" data-symbol-id="GLUE" href="https://stocktwits.com/symbol/GLUE" target="_blank">$GLUE</a>)<figure class="image"><a href="https://stocktwits.com/symbol/GLUE"><img style="aspect-ratio:1284/287;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_28_132438_e581646ba1.png" alt="Screenshot 2024-10-28 132438.png" width="1284" height="287"></a><figcaption>Monte Rosa Therapeutic's sentiment meter as of 1:25 p.m. ET on Oct. 28, 2024 | Source: Stocktwits</figcaption></figure>Shares of Monte Rosa Therapeutics surged over 130% on Monday, reaching a two-year high of $12.15 after&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/glue-stock-enthralls-retail-with-novartis-licensing-deal/cJ2rnM9RJW">announcing an exclusive global licensing agreement with Novartis AG ($NVS).</a>&nbsp;The collaboration focuses on developing innovative treatments for immune-related conditions, particularly MRT-6160, an oral drug designed to inhibit the degradation of VAV1, a key signaling protein for T and B cell receptors.&nbsp;As part of the agreement, Novartis will pay $150 million upfront for exclusive worldwide rights to MRT-6160 and other VAV1-targeting molecular glues, with Monte Rosa eligible for up to $2.1 billion in milestones and tiered royalties on international sales.Retail sentiment on Stocktwits surged to ‘extremely bullish’ (97/100) with ‘extremely high’ (97/100) message volume.Evoke Pharma Inc. (<a class="mention" data-mention="$EVOK" data-symbol-id="EVOK" href="https://stocktwits.com/symbol/EVOK" target="_blank">$EVOK</a>)<figure class="image"><a href="https://stocktwits.com/symbol/EVOK"><img style="aspect-ratio:1282/282;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_28_132459_473ee74b09.png" alt="Screenshot 2024-10-28 132459.png" width="1282" height="282"></a><figcaption>Evoke Pharma's sentiment meter as of 1:25 p.m. ET on Oct. 28, 2024 | Source: Stocktwits</figcaption></figure>Evoke Pharma’s shares were up over 30% on Monday following its presentation of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/evoke-pharma-stock-spikes-higher-on-study-data/cJ2rllaRJO">positive data for its lead drug</a>, Gimoti, as a treatment option for diabetes gastroparesis.The company ranked among the top 10 trending stocks on Stocktwits, secured the second spot for most watched, and was listed in the top 20 most active stocks&nbsp;on Monday afternoon.Evoke Pharma and its partner, Eversana, found that patients using Gimoti, a nasal version of metoclopramide, experienced significant improvements compared to those using the oral formulation. Patients who received the nasal treatment had reduced healthcare resource use and fewer healthcare visits.Retail sentiment on Stocktwits surged into ‘extremely bullish’ territory (97/100) with ‘extremely high’ (97/100) message volume.Autonomix Medical Inc. (<a class="mention" data-mention="$AMIX" data-symbol-id="AMIX" href="https://stocktwits.com/symbol/AMIX" target="_blank">$AMIX</a>)<figure class="image"><a href="https://stocktwits.com/symbol/AMIX"><img style="aspect-ratio:1271/277;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_28_132518_8d6392edf1.png" alt="Screenshot 2024-10-28 132518.png" width="1271" height="277"></a><figcaption>Autonomix Medical's sentiment meter as of 1:25 p.m. ET on Oct. 28, 2024 | Source: Stocktwits</figcaption></figure>Shares of Autonomix skyrocketed by more than 90% on Monday morning following the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/autonomix-stock-rallies-on-strong-trial-results/cJ2rlAHRJf">announcement of positive results from its clinical trial</a> aimed at alleviating pain in pancreatic cancer patients.&nbsp;The stock became the second-highest trending on Stocktwits, just behind Trump Media &amp; Technology Group Corp. ($DJT), and was listed among the top 10 most watched stocks of the day.Retail sentiment on Stocktwits surged to ‘extremely bullish’ (97/100) with chatter escalating into ‘extremely high’ (97/100) territory.For updates and corrections email newsroom@stocktwits.com.Read more: <a href="https://stocktwits.com/news-articles/markets/equity/mstr-stock-hits-all-time-high-as-btc-crosses-68000/cJ2rj2hRJ9">MicroStrategy’s Bitcoin Holdings Drive Historic High: Retail Unfazed</a>

Retail is most bullish on these stocks today | Source: Pexels

Monte Rosa Therapeutics, Evoke Pharma, and Autonomix Medical: The Top 3 Stocks Capturing Retail Attention

Retail sentiment was particularly strong for healthcare stocks today, as Monte Rosa, Autonomix, and Evoke Pharma each announced positive developments regarding their respective innovations.

Shares of nano-cap specialty biopharma Evoke Pharma, Inc. ($EVOK) skyrocketed on Monday following its presentation of positive data for its lead drug Gimoti as a treatment option for diabetes gastroparesis.Solana Beach, California-based Evoke said on Monday that it along with its Eversana, a provider of global commercial services to the life sciences industry, presented data for GLP-1 users with diabetic gastroparesis using Gimoti at the 2024 American College of Gastroenterology annual meeting.The real-world retrospective study that evaluated the impact of Gimoti showed significant reductions across a collection of outcomes observed in patients treated with Gimoti, a nasal formulation of metoclopramide, versus oral formulation of the same, Evoke Pharma said.Patients taking nasal formulation had reduced healthcare resource utilization, and fewer healthcare visits."Our goal is to provide data regarding Gimoti as supportive care for diabetic gastroparesis for those also on GLP-1 agonists. This study, combined with the earlier real-world data presented at key conferences, reinforces GIMOTI's potential to improve outcomes for patients and reduce the overall financial burden on the healthcare system,” said Matt D’Onofrio, CEO of Evoke Pharma.<figure class="image"><a href="https://stocktwits.com/symbol/EVOK"><img style="aspect-ratio:632/132;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/evok_sentiment_973d4ea465.png" alt="evok-sentiment.png" width="632" height="132"></a><figcaption>EVOK sentiment and message volume October 28, 2024, as of 11:05 am ET | Source:&nbsp;Stocktwits</figcaption></figure>Amid the stock rally, retail sentiment toward the stock improved from ‘neutral’ a day ago to ‘extremely bullish’ (97/100) on Monday morning, with message volume spiking to ‘extremely high.’Some among the retail crowd cautioned against selling the stock and said it is worth much more than the level at which it currently traded.<stembedurl>https://stocktwits.com/Shieldsstocks/message/590294090</stembedurl>Gimoti received FDA approval as an option of alleviating symptoms in adults with acute and recurrent diabetic gastroparesis in June 2020.In the second-quarter ended June 30, 2024, Gimoti sales climbed 126% year-over-year and 47% sequentially to $2.55 million. At that time, the company revised up its 2024 net sales guidance from $11 million-$12 million to $14 million, citing the trend seen in the first half of the year.As of 11:05 a.m. ET, Evoke Pharms shares climbed 67.55% to $3.58.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/five-magnificent-seven-companies-are-due-to-release-their-quarterly-score-cards-this-week/cJ2riJORJJ">Apple, Microsoft, Google, Meta, Amazon: How’s Retail Feeling About These Big Tech Stocks Ahead Of Earnings This Week?</a>For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;

Evoke pharma presentation of real-world data for Gimoti at a conference sent its shares soaring.

Evoke Pharma's Retail Sentiment Soars As Stock Rockets On Promising Real-World Data For Gastric Disorder Drug

The real-world retrospective study that evaluated the impact of Gimoti showed significant reductions across a collection of outcomes observed in patients treated with Gimoti.

Evoke Pharma Stock Is Soaring Monday: What's Going On?

Evoke Pharma Inc (NASDAQ:EVOK) shares are trading higher Monday after the company presented GLP-1 data for users with diabetic gastoparesis using GIMOTI showing statistically significant...

Why Evoke Pharma (EVOK) Stock Is Volatile

Evoke Pharma shares were trading lower by 21.4% during Tuesday's session. The company announced a 1-for-12 reverse stock split of its common stock.
read more...

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It also develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.

Evoke Pharma Inc

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.45	--	--	N/A
Q2 '25	-$0.30	-$0.62	-106.67%	MISSED
Q1 '25	-$0.33	-$0.51	-54.55%	MISSED
Q4 '24	-$0.63	-$0.49	22.22%	BEAT
Q3 '24	-$0.38	-$0.94	-147.37%	MISSED

EVOK
Evoke Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '25

Historical Earnings

Latest EVOK News

EVOKEvoke Pharma Inc